Oncothyreon Inc (ONTY) 2.02 $ONTY
Hot Stock: Oncothyreon, Shares Gain 5.3% (ONTY)
Comtex SmarTrend(R) - Fri Dec 12, 10:06AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.3% to $1.80 on 2.8x average daily volume. Oncothyreon has traded 1.4 million shares thus far today, vs. average volume of 508,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -1.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.9%) during today's trading.
ONTY: 2.02 (+0.31)
Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST
ONTY: 2.02 (+0.31), ARRY: 4.86 (-0.04)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 8:16AM CST
FRO: 2.25 (+0.62), GDP: 3.93 (-0.33), TLM: 4.29 (+0.60), ONVO: 6.35 (+0.85), EOX: 0.97 (-0.31), CCXI: 5.60 (+1.11), HCCI: 9.73 (-1.17), ONTY: 2.02 (+0.31), ADBE: 76.02 (+6.28)
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 6:11AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor, will be presented at the San Antonio Breast Cancer Symposium.
ONTY: 2.02 (+0.31)
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 2.02 (+0.31), ARRY: 4.86 (-0.04)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 3.89 (-0.11), BIB: 128.83 (-3.16), INCY: 74.65 (-1.27), PFE: 30.95 (-0.70), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), BIND: 5.82 (+0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), BIS: 46.11 (+0.99), CLVS: 55.15 (+0.32), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), ARIA: 6.34 (-0.13), IRY: 47.43 (-0.71), IXJ: 101.03 (-1.47), FPRX: 22.13 (-1.12)
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:44AM CST
Oncothyreon Inc. (ONTY) was a big mover last session, as the company saw its shares rise slightly over 10% on the day
BIIB: 344.49 (+2.16), ILMN: 184.30 (-2.53), AMAG: 40.04 (-0.79), ONTY: 2.02 (+0.31)
Oncothyreon Up 8.9%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Wed Nov 26, 11:35AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.9% to $1.84 on 1.8x average daily volume. Thus far today, Oncothyreon has traded 817,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's -0.1%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
ONTY: 2.02 (+0.31)
Oncothyreon to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:01AM CST
Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Stifel 2014 Healthcare Conference in New York on Wednesday, Nov. 19, 2014 at 3:00 p.m. Eastern.
ONTY: 2.02 (+0.31)
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
GlobeNewswire - Mon Nov 10, 3:10PM CST
Oncothyreon Inc. (Nasdaq:ONTY) and Celldex Therapeutics, Inc., (Nasdaq:CLDX) today announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes.
CLDX: 18.03 (-0.16), ONTY: 2.02 (+0.31)
Oncothyreon's (ONTY) CEO Robert Kirkman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:04PM CST
ONTY: 2.02 (+0.31)
Oncothyreon posts 3Q loss
Automated Insights - Thu Nov 06, 5:42PM CST
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Thursday reported a loss of $6.7 million in its third quarter.
ONTY: 2.02 (+0.31)
Oncothyreon beats by $0.02
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:49PM CST
ONTY: 2.02 (+0.31)
Oncothyreon Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Oncothyreon Inc. (Nasdaq:ONTY) today reported financial results for the third quarter ended September 30, 2014.
ONTY: 2.02 (+0.31), ARRY: 4.86 (-0.04)
Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its third quarter 2014 financial results and provide a corporate update and review of its pipeline of products in development.
ONTY: 2.02 (+0.31)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.13 (-0.04), BCRX: 10.06 (+0.02), NBIX: 21.97 (+0.12), ONTY: 2.02 (+0.31), DYAX: 14.18 (-0.05)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 91.52 (-1.38), ARQL: 1.25 (unch), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), MRK: 57.72 (-1.62), AEZS: 0.60 (+0.03), GALE: 1.69 (unch), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29), KPTI: 34.85 (+1.35)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 23.66 (+0.24), PSTI: 2.60 (+0.01), ONTY: 2.02 (+0.31)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:44AM CDT
Alexion Pharmaceuticals, Inc. (ALXN) was a big mover last session, as the company saw its shares rise 6% on the day
CBM: 23.66 (+0.24), ALXN: 186.90 (-4.72), ONTY: 2.02 (+0.31)
Traders Get Bullish on Shares of Oncothyreon, Shares Up 10.0% (ONTY)
Comtex SmarTrend(R) - Thu Sep 18, 10:08AM CDT
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 10.0% to $2.20 on 7.3x average daily volume. Thus far today, Oncothyreon has traded 4.3 million shares, vs. average volume of 582,000 shares per day. The stock has outperformed the Dow (10.0% to the Dow's 0.5%) and outperformed the S&P 500 (10.0% to the S&P's 0.4%) during today's trading.
ONTY: 2.02 (+0.31)
Hot Stock: Oncothyreon, Shares Gain 5.3% (ONTY)
Comtex SmarTrend(R) - Fri Dec 12, 10:06AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 5.3% to $1.80 on 2.8x average daily volume. Oncothyreon has traded 1.4 million shares thus far today, vs. average volume of 508,000 shares per day. The stock has outperformed the Dow (5.3% to the Dow's -1.0%) and outperformed the S&P 500 (5.3% to the S&P's -0.9%) during today's trading.
ONTY: 2.02 (+0.31)
Oncothyreon secures exclusive license to HER2 inhibitor
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 9:50AM CST
ONTY: 2.02 (+0.31), ARRY: 4.86 (-0.04)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 8:16AM CST
FRO: 2.25 (+0.62), GDP: 3.93 (-0.33), TLM: 4.29 (+0.60), ONVO: 6.35 (+0.85), EOX: 0.97 (-0.31), CCXI: 5.60 (+1.11), HCCI: 9.73 (-1.17), ONTY: 2.02 (+0.31), ADBE: 76.02 (+6.28)
Oncothyreon Announces Presentation of Positive ONT-380 Data at San Antonio Breast Cancer Symposium
GlobeNewswire - Fri Dec 12, 6:11AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that positive preliminary data from two ongoing Phase 1b trials of ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor, will be presented at the San Antonio Breast Cancer Symposium.
ONTY: 2.02 (+0.31)
Oncothyreon Announces Exclusive License Agreement With Array BioPharma for ONT-380
GlobeNewswire - Fri Dec 12, 6:00AM CST
Oncothyreon Inc. (Nasdaq:ONTY) today announced that Array BioPharma Inc. (Nasdaq:ARRY) has granted Oncothyreon an exclusive license to develop, manufacture and commercialize ONT-380 (ARRY-380), an orally active, reversible and selective small molecule HER2 inhibitor. The license agreement replaces the prior Development and Collaboration Agreement under which Oncothyreon and Array were jointly developing ONT-380.
ONTY: 2.02 (+0.31), ARRY: 4.86 (-0.04)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 3.89 (-0.11), BIB: 128.83 (-3.16), INCY: 74.65 (-1.27), PFE: 30.95 (-0.70), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), BIND: 5.82 (+0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), BIS: 46.11 (+0.99), CLVS: 55.15 (+0.32), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), ARIA: 6.34 (-0.13), IRY: 47.43 (-0.71), IXJ: 101.03 (-1.47), FPRX: 22.13 (-1.12)
Oncothyreon Inc. (ONTY) in Focus: Stock Surges 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:44AM CST
Oncothyreon Inc. (ONTY) was a big mover last session, as the company saw its shares rise slightly over 10% on the day
BIIB: 344.49 (+2.16), ILMN: 184.30 (-2.53), AMAG: 40.04 (-0.79), ONTY: 2.02 (+0.31)
Oncothyreon Up 8.9%, Shares Break Through Resistance (ONTY)
Comtex SmarTrend(R) - Wed Nov 26, 11:35AM CST
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 8.9% to $1.84 on 1.8x average daily volume. Thus far today, Oncothyreon has traded 817,000 shares, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's -0.1%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.
ONTY: 2.02 (+0.31)
Oncothyreon to Present at Stifel 2014 Healthcare Conference
GlobeNewswire - Wed Nov 12, 7:01AM CST
Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Stifel 2014 Healthcare Conference in New York on Wednesday, Nov. 19, 2014 at 3:00 p.m. Eastern.
ONTY: 2.02 (+0.31)
Oncothyreon and Celldex Therapeutics Announce Initiation of Combination Immunotherapy Clinical Trial of ONT-10 and Varlilumab
GlobeNewswire - Mon Nov 10, 3:10PM CST
Oncothyreon Inc. (Nasdaq:ONTY) and Celldex Therapeutics, Inc., (Nasdaq:CLDX) today announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes.
CLDX: 18.03 (-0.16), ONTY: 2.02 (+0.31)
Oncothyreon's (ONTY) CEO Robert Kirkman on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Nov 06, 8:04PM CST
ONTY: 2.02 (+0.31)
Oncothyreon posts 3Q loss
Automated Insights - Thu Nov 06, 5:42PM CST
SEATTLE (AP) _ Oncothyreon Inc. (ONTY) on Thursday reported a loss of $6.7 million in its third quarter.
ONTY: 2.02 (+0.31)
Oncothyreon beats by $0.02
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:49PM CST
ONTY: 2.02 (+0.31)
Oncothyreon Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 3:01PM CST
Oncothyreon Inc. (Nasdaq:ONTY) today reported financial results for the third quarter ended September 30, 2014.
ONTY: 2.02 (+0.31), ARRY: 4.86 (-0.04)
Oncothyreon Announces Third Quarter 2014 Financial Results Conference Call
GlobeNewswire - Thu Oct 30, 7:00AM CDT
Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 6, 2014 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific) to discuss its third quarter 2014 financial results and provide a corporate update and review of its pipeline of products in development.
ONTY: 2.02 (+0.31)
Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 14.13 (-0.04), BCRX: 10.06 (+0.02), NBIX: 21.97 (+0.12), ONTY: 2.02 (+0.31), DYAX: 14.18 (-0.05)
Endometrial Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 5:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wds2pr/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Bristol-Myers Squibb - Sanofi - GlaxoSmithKline - Daiichi Sankyo - Merck & Co - Novartis - BioMarin Pharmaceutical - Eisai - ImmunoGen - Genmab - Exelixis - AEterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Oncothyreon Inc. - Critical Outcome Technologies Inc. - ArQule, Inc. - Galena Biopharma, Inc. - Scancell Holdings Plc - Oryzon Genomics S.A. - Acceleron Pharma, Inc. - Arno Therapeutics, Inc. - Endocyte, Inc. - Esperance Pharmaceuticals, Inc. - Pharmsynthez - Shenogen Pharma Group Ltd. - Igenica Biotherapeutics, Inc. - Karyopharm Therapeutics, Inc. - OncoHoldings, Inc. For more information visit http://www.researchandmarkets.com/research/wd...ndometrial
BMRN: 91.52 (-1.38), ARQL: 1.25 (unch), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), MRK: 57.72 (-1.62), AEZS: 0.60 (+0.03), GALE: 1.69 (unch), NVS: 93.52 (-0.82), XLRN: 41.77 (+0.29), KPTI: 34.85 (+1.35)
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 07, 7:44AM CDT
Pluristem Therapeutics, Inc. (PSTI) was a big mover last session, as the company saw its shares rise over 7% on the day
CBM: 23.66 (+0.24), PSTI: 2.60 (+0.01), ONTY: 2.02 (+0.31)
Alexion Pharmaceuticals (ALXN) in Focus: Stock Rises 6.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 7:44AM CDT
Alexion Pharmaceuticals, Inc. (ALXN) was a big mover last session, as the company saw its shares rise 6% on the day
CBM: 23.66 (+0.24), ALXN: 186.90 (-4.72), ONTY: 2.02 (+0.31)
Traders Get Bullish on Shares of Oncothyreon, Shares Up 10.0% (ONTY)
Comtex SmarTrend(R) - Thu Sep 18, 10:08AM CDT
Oncothyreon (NASDAQ:ONTY) is one of today's best performing low-priced stocks, up 10.0% to $2.20 on 7.3x average daily volume. Thus far today, Oncothyreon has traded 4.3 million shares, vs. average volume of 582,000 shares per day. The stock has outperformed the Dow (10.0% to the Dow's 0.5%) and outperformed the S&P 500 (10.0% to the S&P's 0.4%) during today's trading.
ONTY: 2.02 (+0.31)
